Telix Pharmaceuticals Limited (ASX:TLX) shares were priced at $15.41 on 6 October 2026, down 0.90% on the day, and are up 0.65% over the past twelve months and nearly 13% in last 6 months. The radiopharmaceutical company announced on 30 September 2026 that the US Food and Drug Administration (FDA) has granted Fast Track Designation for its BiPASS program. The company is also listed on Nasdaq under the same ticker.

Across the broader market, the S&P/ASX 200 Health Care index [XHJ] (INDEXASX: XHJ) stood at 31,982.20, up 0.63% (+200.50 points) as of 6 October, and is down 16% over the past year. Meanwhile, the S&P/ASX 200 stood at 8,735.70, up 0.57% (+49.30 points) at the same time, and is down 2.74% over the year.

Business Model and Operational Footprint

Telix is a commercial-stage global radiopharmaceutical company advancing targeted theranostics, which pair a precision diagnostic with a targeted therapy to diagnose and treat disease. Headquartered in Melbourne, it has operations across North America, Europe, Latin America and Asia-Pacific, with a US presence in Indianapolis.

Its commercial Franchise is anchored by diagnostics: Illuccix, a kit for gallium-68 gozetotide injection commercially available in 22 countries including the United States, Gozellix, approved by the FDA for prostate imaging, and Pixclara, approved by the FDA for glioma imaging. The late-stage therapeutic pipeline includes three investigational Assets in pivotal-stage trials: TLX591-Tx (lutetium-177 rosopatamab tetraxetan) in prostate cancer, TLX101-Tx (iodofalan 131I) in recurrent glioblastoma and TLX250-Tx (lutetium-177 girentuximab tetraxetan) in kidney cancer. None of these three has received Marketing authorisation in any jurisdiction.

Sector Dynamics

Prostate cancer diagnosis often involves biopsy. According to the references cited in the announcement, more than three million prostate biopsies are performed globally each year, and up to 75% produce a negative result. The announcement describes biopsy as potentially stressful and painful for patients, and says it may provide no meaningful diagnostic benefit in some cases.

Imaging-first approaches, in which PSMA-PET imaging is used alongside MRI before a biopsy decision, are an active area of clinical research. The FDA's Fast Track process is designed to facilitate development and expedite review of drugs that treat serious conditions and Fill an unmet medical need, potentially accelerating patient access if approved.

Press Release Details

The FDA granted Fast Track designation to BiPASS (Biopsy of the Prostate Avoidance Stratification Study), which is evaluating gallium-68 PSMA-PET imaging in combination with MRI for detecting prostate cancer before biopsy. The designation recognises the program's potential to address an unmet need by enabling an imaging-first approach to initial diagnosis. It allows more frequent engagement with the FDA and may enable expedited review of the planned new drug application (NDA).

Telix has completed enrolment in the Phase 3 BiPASS study of Illuccix and Gozellix for pre-biopsy diagnosis. The company has engaged with the FDA on an NDA pathway and is planning a submission, which would register the product as new and, if approved, widen access to 68Ga-PSMA-PET imaging for a larger patient population.

The program builds on the PRIMARY and PRIMARY2 studies, which reported that combining 68Ga-PSMA-PET with MRI can significantly improve detection of clinically significant prostate cancer while reducing unnecessary biopsies by almost 50 percent. BiPASS is not intended to replace biopsy where it benefits the patient but to help clinicians decide which patients would benefit from biopsy and where to target it. Group Chief Medical Officer Dr David Cade said the designation reflects the FDA's recognition of the potential for BiPASS to address an unmet need.

Illuccix and Gozellix are approved for PET imaging of PSMA-positive lesions in patients with prostate cancer with suspected metastasis who are candidates for initial definitive therapy, and in patients with suspected recurrence based on elevated PSA. Illuccix is also approved for selecting patients for PSMA-directed therapy. Use in the pre-biopsy setting remains investigational and has not been approved by the FDA or any other regulatory authority.

Growth Catalysts and Critical Operating Risks

Items identified in the announcement include the planned NDA submission for BiPASS, closer FDA engagement under Fast Track, the possibility of expedited review, and the broadening of access to PSMA-PET imaging if the NDA is approved. The company's portfolio of three late-stage therapeutic candidates and its commercial diagnostics products form the wider context.

The announcement states the risks plainly. Fast Track designation does not itself approve a product. The pre-biopsy use of Illuccix and Gozellix is investigational, the NDA has not yet been submitted, and the three therapeutic candidates have not received marketing authorisation anywhere. The legal notices refer to risks in clinical trials, regulatory filings and approvals, Manufacturing and supply, commercialisation, pricing and reimbursement, competition, and the anticipated impact of US and foreign tariffs and geopolitical conflicts. Actual results may differ materially from forward-looking statements.

Telix said its commercial franchise is anchored by precision diagnostics, with Illuccix available in 22 countries. The company's Group Chief Medical Officer said the designation supports continued close engagement with the FDA as the company advances BiPASS toward an NDA submission. The announcement was authorised for release by the company's Disclosure Committee on behalf of the Board and contains standard legal notices covering forward-looking statements and trademarks.

The Bottom Line

Telix's 30 September 2026 announcement concerns a regulatory designation rather than financial results. BiPASS has received FDA Fast Track status, Phase 3 enrolment is complete and an NDA submission is being planned. The company's shares are up 0.65% over twelve months and down 0.90% on the day, and the pre-biopsy indication remains investigational.